Biren Amin
Stock Analyst at Piper Sandler
(2.44)
# 2,494
Out of 5,050 analysts
65
Total ratings
52.63%
Success rate
-1.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Biren Amin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AAPG Ascentage Pharma Group International | Initiates: Overweight | $48 | $31.73 | +51.28% | 1 | Nov 5, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $15 → $16 | $17.63 | -9.25% | 12 | Oct 30, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $93 → $98 | $61.80 | +58.58% | 4 | Oct 30, 2025 | |
| LENZ LENZ Therapeutics | Maintains: Overweight | $51 → $67 | $22.97 | +191.68% | 2 | Oct 10, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Overweight | $21 → $31 | $10.85 | +185.71% | 2 | Oct 3, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Overweight | $76 → $95 | $80.95 | +17.36% | 2 | Sep 25, 2025 | |
| ACRS Aclaris Therapeutics | Assumes: Overweight | $6 | $2.32 | +158.62% | 1 | Jul 10, 2025 | |
| CNTX Context Therapeutics | Reiterates: Overweight | $4.5 → $4 | $1.12 | +257.14% | 1 | Jun 26, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $20 → $17 | $4.06 | +318.72% | 2 | May 16, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Overweight | $9 → $7 | $1.18 | +493.22% | 3 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $22.12 | +71.79% | 1 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $4.23 | +183.69% | 1 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $71 | $36.77 | +93.09% | 2 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $10.52 | +232.70% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $15.24 | +37.80% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $115 | $86.55 | +32.87% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $32 | $19.26 | +66.15% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $7 → $3 | $3.98 | -24.62% | 1 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $70 | $1.28 | +5,368.75% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $0.69 | +7,327.91% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $4.69 | +411.73% | 1 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $3.83 | +787.73% | 1 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,050 → $500 | $0.71 | +69,937.82% | 2 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $9.05 | +54.78% | 1 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $657 → $691 | $657.53 | +5.09% | 2 | Jun 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $10 | $3.62 | +176.24% | 1 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $101 | $39.65 | +154.73% | 1 | Nov 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $152.37 | -54.72% | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $155 | $409.47 | -62.15% | 5 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $3.71 | +3,565.77% | 4 | Mar 6, 2017 |
Ascentage Pharma Group International
Nov 5, 2025
Initiates: Overweight
Price Target: $48
Current: $31.73
Upside: +51.28%
Sarepta Therapeutics
Oct 30, 2025
Maintains: Neutral
Price Target: $15 → $16
Current: $17.63
Upside: -9.25%
BridgeBio Pharma
Oct 30, 2025
Maintains: Overweight
Price Target: $93 → $98
Current: $61.80
Upside: +58.58%
LENZ Therapeutics
Oct 10, 2025
Maintains: Overweight
Price Target: $51 → $67
Current: $22.97
Upside: +191.68%
Ocular Therapeutix
Oct 3, 2025
Maintains: Overweight
Price Target: $21 → $31
Current: $10.85
Upside: +185.71%
Monopar Therapeutics
Sep 25, 2025
Maintains: Overweight
Price Target: $76 → $95
Current: $80.95
Upside: +17.36%
Aclaris Therapeutics
Jul 10, 2025
Assumes: Overweight
Price Target: $6
Current: $2.32
Upside: +158.62%
Context Therapeutics
Jun 26, 2025
Reiterates: Overweight
Price Target: $4.5 → $4
Current: $1.12
Upside: +257.14%
Solid Biosciences
May 16, 2025
Maintains: Overweight
Price Target: $20 → $17
Current: $4.06
Upside: +318.72%
Allogene Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $9 → $7
Current: $1.18
Upside: +493.22%
Mar 31, 2025
Initiates: Overweight
Price Target: $38
Current: $22.12
Upside: +71.79%
Feb 19, 2025
Initiates: Overweight
Price Target: $12
Current: $4.23
Upside: +183.69%
Feb 6, 2025
Maintains: Overweight
Price Target: $74 → $71
Current: $36.77
Upside: +93.09%
Dec 2, 2024
Initiates: Overweight
Price Target: $35
Current: $10.52
Upside: +232.70%
Nov 14, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $15.24
Upside: +37.80%
Nov 8, 2024
Maintains: Overweight
Price Target: $91 → $115
Current: $86.55
Upside: +32.87%
Nov 6, 2024
Maintains: Neutral
Price Target: $40 → $32
Current: $19.26
Upside: +66.15%
Jul 19, 2024
Downgrades: Hold
Price Target: $7 → $3
Current: $3.98
Upside: -24.62%
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $1.28
Upside: +5,368.75%
Jan 11, 2021
Initiates: Buy
Price Target: $51
Current: $0.69
Upside: +7,327.91%
Oct 30, 2020
Initiates: Buy
Price Target: $24
Current: $4.69
Upside: +411.73%
Oct 19, 2020
Initiates: Buy
Price Target: $34
Current: $3.83
Upside: +787.73%
Sep 14, 2020
Downgrades: Hold
Price Target: $1,050 → $500
Current: $0.71
Upside: +69,937.82%
Jul 24, 2020
Initiates: Buy
Price Target: $14
Current: $9.05
Upside: +54.78%
Jun 12, 2020
Maintains: Buy
Price Target: $657 → $691
Current: $657.53
Upside: +5.09%
Jun 1, 2020
Downgrades: Hold
Price Target: $16 → $10
Current: $3.62
Upside: +176.24%
Nov 9, 2017
Initiates: Buy
Price Target: $101
Current: $39.65
Upside: +154.73%
Oct 3, 2017
Maintains: Buy
Price Target: $66 → $69
Current: $152.37
Upside: -54.72%
Jul 11, 2017
Initiates: Buy
Price Target: $155
Current: $409.47
Upside: -62.15%
Mar 6, 2017
Initiates: Buy
Price Target: $136
Current: $3.71
Upside: +3,565.77%